# Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation.

> PubMed lists PMID 42155604 in Diabetes research and clinical practice as Letter, with publication-date metadata of 2026-05-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42155604-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42155604-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42155604-tirzepatide-v1.json
- Content SHA-256: `93159433ace5dcf8a987cd8f4db9339a1b63caa0113437fcacb0f268eeb69058`

## Claims and source pins

### Headline

Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation. ([`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`](#source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39))

### Summary

PubMed lists PMID 42155604 in Diabetes research and clinical practice as Letter, with publication-date metadata of 2026-05-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`](#source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39))

### Paragraph 1

PubMed lists PMID 42155604 in Diabetes research and clinical practice as Letter, with publication-date metadata of 2026-05-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`](#source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`](#source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39))

## Sources

<a id="source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39"></a>
- **Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation. · retained source version 1:2026-06-06:current:3ec65c22ac3905250f69163294adeb6b784d67850a8073ac13b1ae0550327d40** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42155604/) (`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42155604-tirzepatide-v1.json SHA-256: 93159433ace5dcf8a987cd8f4db9339a1b63caa0113437fcacb0f268eeb69058.